For example, Theratope (Biomira), GM2-KLH (Memorial Sloan Kettering Cancer Center), OPT-822 (OBI Pharma), and Racotumomab (Molecular Immunology Center in Havana) targeting sTn antigen, ganglioside GM2, glycolipid Globo H, and ganglioside GM3, respectively, surpassed phase III trials. The gene discussed is EEF1A2; the disease is cancer.